Objective: To evaluate the effect of vitamin D 3 on blood pressure in people with vitamin D deficiency.
Introduction
Vitamin D is 1 kind of steroid hormone. It can promote the absorption of calcium, phosphorus and other elements in the gastrointestinal tract. Vitamin D plays a key role in the skeleton and mineral metabolism which is an importance of human health. [1] The Institution of Endocrinology Clinical Practice Guidelines [2] pointed out that vitamin D deficiency was defined as a serum 25-hydroxyvitamin D (25-OHD) content less than 20ng/ mL (or 50 nmol/L). Vitamin D deficiency is prevalent in Chinese population with. [3] There is a large volume of published studies describing that vitamin D deficiency can not only cause osteoporosis or other common diseases, but also lead to cardiovascular diseases, metabolic diseases, and tumors. Hypertension is an important factor that causes cardiovascular disease. Recent evidence indicated that serum 25-OHD levels were negatively correlated with the risk of hypertension. [4] It is considered that blood pressure changes in people with vitamin D deficiency would be related to vitamin D supplementation. This study aims to compare the changes in blood pressure in people with vitamin D deficiency after administration of vitamin D 3 by meta-analysis.
Methods

Search strategy
CNKI, VIP, WanFang Data, The Cochrane Library, PubMed, and Embase were searched by tow reviewers independently by computer from the database to December 2017. The search terms included vitamin D 3 , cholecalciferol, and 25-OHD. Randomized controlled trials (RCTs) published in English language which were reported the effects of vitamin D 3 supplementation in people with vitamin D deficiency on blood pressure would be included.
Inclusion and exclusion criteria
The subjects were people with vitamin D deficiency. The baseline serum 25-OHD of them should be lower than 20ng/mL (or 50nmol/L). The RCTs mentioned that the observation group was administered a dose of vitamin D 3 and the control group was the placebo. The subjects were with no vitamin D deficiency and the form of vitamin D was not mentioned in the articles as vitamin D 3 was not included. Articles that data cannot be extracted from were not included. Studies that were published repeatedly were included only once. No ethical review is needed in this study.
Data extraction
The 2 reviewers extracted the data according to inclusion and exclusion criteria, then used self-made Excel forms and handdrawn forms to record data. Mean age, male ratio, body mass index (BMI), mean serum 25-OHD baseline, sample size, subjects, nationality (or ethnicity), intervention measures, and course of treatment from the studies were extracted.
Quality assessment
The quality of studies was assessed via using the Cochrane Handbook: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. Publication bias was generated by using a funnel plot to examine whether there was a bias towards studies.
Data synthesis and analysis
Data synthesis and analysis were carried out by RevMan 5.3 software and Stata 14.0 software. Relative risk (RR) was used as the statistic of curative effect analysis, and weighted mean difference (WMD) was used as the statistic of continuous variables. 95% confidence interval (CI) was given as the statistic of curative effect analysis. Heterogeneity analysis was performed by x 2 statistics. Fixed effect model was used when P >.1 and I 2 < 50% and random effect model was used when P <.1 or I 2 ≥50%. The mean changes of systolic pressure (DSBP) and the mean changes of DBP (DDBP) were performed to evaluate the effects of vitamin D 3 of intervention groups and placebo of control groups. If the DSBP or DDBP are not mentioned in the articles, the mean and SD of DSBP and DDBP should be calculated by formulas. 
Results
Study selection
The screening process is detailed in Figure 1 . A total of 861 published articles were screened. Of those articles, 174 were first excluded due to duplicate publications. 575 were excluded after reading the titles and abstracts and then 112 articles were further screened. 62 of these did not fit the specific inclusion criteria and data from 33 articles cannot be extracted. Finally, a total of 17 RCTs [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] were included, including 22 arms and 1687 participants.
Study characteristics
The characteristics of the studies are shown in Table 1 . The mean serum 25-OHD of the participants from all articles are lower than 20ng/mL (or 50 nmol/L). The mean age of the participants is between 18 and 74 years old. The duration of intervention is 6 weeks to 12 months. Participants of 5 articles were hypertension. 5 arms of 3 articles were diabetic participants. The BMI is between 23.9 and 36.1.
Quality assessment
The quality evaluation of the study is shown in Figure 2 . 17 RCTs were all double-blind and reported dropouts. There were no selective reports or other sources of bias that were mentioned in the articles. Only 3 articles [5, 8, 14] were not explained the randomization methods. Only 5 references [11, [16] [17] [18] [19] were used the correct allocation concealment. All of the 17 articles included are of high quality. Table 2 .
Publication bias
There was no publication bias based on Egger test (t = À0.95, P = .355 for DSBP, t = À0.48, P = .634 for DDBP, Fig. 4 ).
Discussion and conclusion
Vitamin D 3 is one of the most active forms of vitamin D with the highest biometabolic rate. It is synthesized in skin by ultraviolet radiation and is less obtained from usual diet. A meta-analysis [22] of 7 RCTs indicated that vitamin D 3 is more efficacious at increasing serum 25-OHD than is vitamin D 2 , and vitamin D 3 supplementation intake was the preferred treatment for vitamin D deficiency. [23] Numerous studies have attempted to explain the possible mechanisms of vitamin D deficiency that induced hypertension. Presently, there are 3 mainstream theories: First, it is that the renin-angiotensin-aldosterone system (RAAS) is activated. An animal experiment has shown that mice lacking the vitamin D receptor has had elevated production of renin and angiotensin II. [24] The second is vitamin D deficiency leads to hyperparathyroidism. Serum 25-OHD levels and parathyroid hormone (PTH) levels are negatively correlated and high PTH level causes hypertension. The last is that vitamin D deficiency causes endothelial dysfunction. The reducing of NO in the blood vessels caused by endothelial dysfunction affects the vasodilation and then raised blood pressure. It suggests that vitamin D deficiency might be a risk factor of hypertension.
All the studies reviewed so far, however, the RCTs included from each study had larger individual differences and the conclusions of them are not the same. The relationship between vitamin D 3 and blood pressure has been widely investigated in several previous meta-analysis. For the purpose of exploring the relationship between vitamin D deficiency and blood pressure, a total of 17 articles including 22 arms involving 1687 participants were included in this study. The results showed that vitamin D 3 made no effect on DSBP or DDBP in people with vitamin D deficiency. A meta-analysis of Beveridge [26] shown no effect of vitamin D supplementation was seen on SBP or DBP in the subgroup of mean baseline 25OHD level 20 ng/mL. In this study, another 3 RCTs were included which were published after Beveridge's study. Furthermore, the participants of Beveridge's study were administered vitamin D2 , vitamin D3 or 1-a-Hydroxylated vitamin D and participants of this study were only administered vitamin D3. These reasons may lead to different conclusions of the 2 studies. Another meta-analysis in 2016 including 30 RCTs by Golzarand [25] reported that there was no significant difference in the effects of vitamin D3 supplementation on systolic and diastolic blood pressure. The conclusion was similar to this study but the participants in that study were not limited to vitamin D deficiency. This is the first meta-analysis of blood pressure after vitamin D3 supplementation for people with vitamin D deficiency.
In this subgroup analysis, there is a significant difference in the group of age >50. There is an evidence suggests that the prevalence of hypertension increases from age. [27] The ability to absorb and metabolize vitamin D of humans decreases in age growing, resulting in vitamin D deficiency in the elderly. The systolic blood pressure on vitamin D deficient folks whose age over 50 years old will decrease significantly when their vitamin D Medicine levels returned to normal after vitamin D 3 supplementation. The differences between the observation group and control group of DSBP and DDBP in the hypertension subgroup are statistically significant. The results of subgroup analysis from Wei Zhen's meta-analysis [28] published in 2017 showed that oral vitamin D 3 supplementation could reduce the systolic and diastolic blood pressure levels in patients with essential hypertension, but could not affect the blood pressure level in people without hypertension. It was similar to the subgroup analysis in this study. It is concluded that vitamin D 3 has a hypotensive effect on hypertension patients but useless on non-hypertension patients. The difference of DSBP is statistically significant in BMI >30 subgroup. BMI index is positively correlated with blood pressure level. The aggregate analysis of the follow-up data of 240,000 Chinese adults shows that the risk of hypertension in people with BMI >24 is over triple higher than that in people with normal weight. [27] Overweight or obese people are prone to vitamin D deficiency because they lack of exercise and rarely stay outside under ultraviolet radiation. Increased activity in these groups not only reduces body weight but also reduces the risk of hypertension by synthesizing vitamin D from skin exposure to ultraviolet light. Intervention duration less than 6 months, average daily dose over 800IU/d and daily doses appeared to be more effective at reducing blood pressure in the meta-analysis of Golzarand. [25] However, the daily dosage of vitamin D3, intervention measures or the course of treatment are not the factors that influenced the outcomes in this study. Limitations of this study are as follows:
(1) This study may have language bias because all the RCTs included are in English. 3) The participants from quite a few RCTs included in this study took other non-experimental drugs at the same time in the observation group and control group that may affect the reliability of the results. (4) Only RCTs were included in these studies. More multi-center, large-sample, well-designed clinical reports and prospective studies are needed to further summarize this study.
In conclusion, vitamin D 3 can be taken as a prophylactic drug for hypertension by the elderly and obese folks with vitamin D deficiency who are at high risk of hypertension. Vitamin D 3 can be used as an adjuvant drug to control the blood pressure on hypertension patients with vitamin D deficiency. 
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